Cargando…

Nivolumab to pembrolizumab switch induced a durable melanoma response: A case report

RATIONALE: While checkpoint inhibitors have revolutionized the treatment of melanoma, it is not known whether switching from one monoclonal antibody drug to another one would be justified in the case of a treatment failure. Herein, we report a case illustrating a durable response to pembrolizumab af...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lepir, Tanja, Zaghouani, Mehdi, Roche, Stéphane P., Li, Ying-Ying, Suarez, Miguel, Irias, Maria Jose, Savaraj, Niramol
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336603/ https://www.ncbi.nlm.nih.gov/pubmed/30633154 http://dx.doi.org/10.1097/MD.0000000000013804

Ejemplares similares

Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma
por: Gupta, Mehul, et al.
Publicado: (2023)

Durable Response with Single-Agent Pembrolizumab in a Patient with Metastatic Melanoma
por: Cyriac, Sanju, et al.
Publicado: (2021)

BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma
por: Li, Ying-Ying, et al.
Publicado: (2016)

Into the Clinic With Nivolumab and Pembrolizumab
por: Shu, Catherine A., et al.
Publicado: (2016)

Time to Treatment With Nivolumab or Pembrolizumab for Patients With Advanced Melanoma in Everyday Practice
por: Ksienski, Doran, et al.
Publicado: (2021)

Molecular Farming of Pembrolizumab and Nivolumab
por: Stark, Michael C., et al.
Publicado: (2023)

Degradation of AMPK‐α1 sensitizes BRAF inhibitor‐resistant melanoma cells to arginine deprivation
por: Li, Ying‐Ying, et al.
Publicado: (2017)

Enhancing the Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Signaling and Arginine Deprivation in Melanoma
por: Wu, Chunjing, et al.
Publicado: (2021)

RNA editing signatures identify melanoma patients who respond to Pembrolizumab or Nivolumab treatment
por: Siddiqui, Jalal, et al.
Publicado: (2021)

Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin
por: Savaraj, Niramol, et al.
Publicado: (2015)

The Relationship of Arginine Deprivation, Argininosuccinate Synthetase and Cell Death in Melanoma
por: Savaraj, Niramol, et al.
Publicado: (2007)

Efficacy of Pembrolizumab and Nivolumab in Crossing the Blood Brain Barrier
por: Abid, Haisam, et al.
Publicado: (2019)

Complete and durable response of pulmonary large‐cell neuroendocrine carcinoma to pembrolizumab
por: Kadota, Naoki, et al.
Publicado: (2021)

Durable response to pembrolizumab in microsatellite instability‐high advanced adrenocortical carcinoma
por: Senda, Masaya, et al.
Publicado: (2023)

Case Report: Durable complete pathologic response and organ preservation following ipilimumab and nivolumab for locally advanced primary vaginal mucosal melanoma
por: Tarhini, Ahmad A., et al.
Publicado: (2022)

Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
por: Chen, Yen-Hao, et al.
Publicado: (2023)

Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain–Barré Syndrome
por: Cortellini, Alessio, et al.
Publicado: (2018)

Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes
por: Kuo, Macus Tien, et al.
Publicado: (2010)

Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis
por: Ide, Maako, et al.
Publicado: (2018)

A Durable Response after the Discontinuation of Nivolumab in an Advanced Gastric Cancer Patient
por: Yatsuda, Yukino, et al.
Publicado: (2020)

Long-term response of vulvar mucosal melanoma treated with neoadjuvant nivolumab
por: Dubus, Margaux, et al.
Publicado: (2023)

Complete and Durable Response After Radiation Therapy to Primary Tumor Site of a Patient With Metastatic Anorectal Mucosal Melanoma With Oligoprogression on Nivolumab
por: Wallington, David G., et al.
Publicado: (2020)

Comparative effectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC
por: Cui, Pengfei, et al.
Publicado: (2020)

Durable Complete Response to Pembrolizumab in Esophageal Squamous Cell Carcinoma With Divergent Microsatellite Status: A Case Report
por: Zeng, Tian, et al.
Publicado: (2021)

Collaboration Between RSK-EphA2 and Gas6-Axl RTK Signaling in Arginine Starvation Response That Confers Resistance to EGFR Inhibitors
por: Kuo, Macus Tien, et al.
Publicado: (2019)

Long-term durable responses after pembrolizumab immunotherapy for recurrent, resistant endometrial cancer
por: Chan, John K., et al.
Publicado: (2020)

Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer
por: Gorshein, Elan, et al.
Publicado: (2021)

Pembrolizumab-Induced Vitiligo in Esophageal Squamous Cell Carcinoma Patient With Durable Complete Response
por: Wilkins, Matthew C, et al.
Publicado: (2021)

Mediastinal Malignant Melanoma Markedly Shrinking in Response to Nivolumab
por: Sakaguchi, Hiroyuki, et al.
Publicado: (2021)

Single pembrolizumab treatment causing profound durable response in a patient with pulmonary pleomorphic carcinoma
por: Tokuyasu, Hirokazu, et al.
Publicado: (2019)

Biomarkers and Gene Signatures to Predict Durable Response to Pembrolizumab in Non-Small Cell Lung Cancer
por: Poma, Anello Marcello, et al.
Publicado: (2021)

A single dose of pembrolizumab treatment causing a profound and durable response in lung cancer
por: Kondo, Yoshihiro, et al.
Publicado: (2022)

A complete durable response of vaginal clear cell carcinoma with pembrolizumab: A case report
por: Porragas-Paseiro, Hector S., et al.
Publicado: (2023)

Efficacy of pembrolizumab for advanced/metastatic melanoma: a meta-analysis
por: Zhang, Qi, et al.
Publicado: (2020)

Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma
por: Feun, Lynn G, et al.
Publicado: (2018)

Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer
por: Wang, Chongkai, et al.
Publicado: (2020)

Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center
por: Hall, Evan, et al.
Publicado: (2020)

Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors
por: Wong, Jeffrey Sum Lung, et al.
Publicado: (2021)

Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma
por: Kuo, Hsin-Yu, et al.
Publicado: (2022)

Spotlight on pembrolizumab in the treatment of advanced melanoma
por: Rajakulendran, Thanashan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_sfen9atroh2evsaqt55ms4jqs6